검색어: ispe�ji (몰타어 - 영어)

jridu ji¡u
have to be

dan jista ’ ji ri:
this might happen: • if you take too much insulin • if you eat too little or miss a meal • if you exercise more than usual.

) u l-l in ji ta
) and the

- ċivili er ji d li huma
, such as e h t. c , et vi de nc e (under

- p r in ċ i p ji ta
ichr w it h the

uffi``ji u bureau ta' informazzjoni
archive and documentation centre

assorbiment ma ji ix affettwat mill- ikel.
olanzapine can be given without regards for meals as absorption is not affected by food.

- xhud en za legali t er ji ’ ma
y and of the

, bil-g¢an li ji¿u protetti
closed periods and zones

il-programm ta’ xogħol ji dde prestazzjoni.
the work programme de indicators.

- istat m er ji ċivili u ku m m er t ma
on fe re nc in g in c ro ss oc e qu es tin g cr our c our c

(il-kunsill) potenzjali ċċ ji tte x?
(council) ts ts

55 li e rti nanzjar ji, tekniki, ta’ er ti.
55 er ed from the e ct ing pr ec ise requirements against which to ju dg e and co m p are competing bids n an ci al , technical, management ). (

, ikun iku un njista’ j ji ista’ jippreżenta j ji ippreżżenta
states’ in favour of enlargement.

) li ilhom ji¿u applikati g¢al bosta snin.
6 conditions set out in article 1 of council directive 83/349/eec on consolidated accounts (), which has been applied for many years.

dawn g¢andhom ji¿u msa¢¢a fil-futur.
these features should be strengthened in thefuture.

disinn(ji) tal-combustion chamber u piston crown:
drawing(s) of combustion chamber and piston crown:

13dawn il-ftehimiet ji¿ormaw il-bażi legali tar-relazzjonijiet
the enpi regulation requires multiannual programmingand strategy papers.

barra minn hekk, g andu ji i ppre entat rmp a ornat • meta ti i r evuta informazzjoni dida li jista ’ jkollha impatt fuq l- ispe ifikazzjoni tas- sigurtà attwali, fuq il- pjan tal- farmakovi ilanza jew fuq l- attivitajiet li jnaqqsu r- riskji • fi mien 60 jum minn meta tintla aq mira importanti (farmakovi ilanza jew tnaqqis tar- riskji) • fuq talba ta ’ l- emea
in addition, an updated rmp should be submitted • when new information is received that may impact on the current safety specification, pharmacovigilance plan or risk minimisation activities • within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • at the request of the emea